Renal Uptake and Tolerability of a 2'-O-methoxyethyl Modified Antisense Oligonucleotide (ISIS 113715) in Monkey
Overview
Authors
Affiliations
The primary target organ for uptake of systemically administered phosphorothioate oligonucleotides is the kidney cortex and the proximal tubular epithelium in particular. To determine the effect of oligonucleotide uptake on renal function, a detailed renal physiology study was performed in cynomolgus monkeys treated with 10-40 mg/kg/week ISIS 113715 for 4 weeks. The concentrations of oligonucleotide in the kidney cortex ranged from 1400 to 2600 μg/g. These concentrations were associated with histologic changes in proximal tubular epithelial cells that ranged from the appearance of cytoplasmic basophilic granules to atrophic and degenerative changes at higher concentrations. However, there were no renal functional abnormalities as determined by the typical measurements of blood urea nitrogen, serum creatinine, creatinine clearance, or urine specific gravity. Nor were there changes in glomerular filtration rate, or renal blood flow. Specific urinary markers of tubular epithelial cell damage, such as N-acetyl-glucosaminidase, and α-glutathione-s-transferase were not affected. Tubular function was further evaluated by monitoring the urinary excretion of amino acids, β(2)-microglobulin, or glucose. Renal function was challenged by administering a glucose load and by examining concentrating ability after a 4-h water deprivation. Neither challenge produced any evidence of change in renal function. The only change observed was a low incidence of increased urine protein/creatinine ratio in monkeys treated with ≥40 mg/kg/week which was rapidly reversible. Collectively, these data indicate that ISIS 113715-uptake by the proximal tubular epithelium has little or no effect on renal function at concentrations of 2600 μg/g.
Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy.
Silva J, da Costa Martins P Cells. 2022; 11(11).
PMID: 35681500 PMC: 9180404. DOI: 10.3390/cells11111805.
Rath P, Ranjan A, Ghosh A, Chauhan A, Gurnani M, Tuli H Molecules. 2022; 27(7).
PMID: 35408611 PMC: 9000704. DOI: 10.3390/molecules27072212.
Nishina H, Sakairi T, Kashimura A, Sato H, Mizukawa M, Ozawa Y J Toxicol Pathol. 2021; 34(4):367-371.
PMID: 34629736 PMC: 8484925. DOI: 10.1293/tox.2021-0007.
Valenzuela A, Tardiveau C, Ayuso M, Buyssens L, Bars C, Van Ginneken C Pharmaceutics. 2021; 13(9).
PMID: 34575518 PMC: 8470776. DOI: 10.3390/pharmaceutics13091442.
Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
Aoki Y, Wood M J Neuromuscul Dis. 2021; 8(6):869-884.
PMID: 34092651 PMC: 8673547. DOI: 10.3233/JND-200560.